Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$23.58 USD
-1.53 (-6.08%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $23.57 -0.01 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Arrowhead Pharmaceuticals, Inc. [ARWR]
Reports for Purchase
Showing records 81 - 92 ( 92 total )
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Neutral Lowering to Neutral on reaching price target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Reported financial results for their Q3/2013 quarter
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Initiating coverage with a BUY rating and 12-18 month price target of $4.00 per share
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
A FOUR STAR PATENTVEST IP VALUE COMPANY -2011 "BEST AND BRIGHTEST" PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC